3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Interventions
pembrolizumab
91
Carboplatin
73
Pemetrexed
58
Nivolumab
50
Docetaxel
47
Cisplatin
47
Paclitaxel
46
Erlotinib Hydrochloride
37
Radiotherapy
30
Gemcitabine
27
osimertinib
23
Cetuximab
23
Bevacizumab
21
Ipilimumab
18
Radiosurgery
14
130-nm albumin-bound paclitaxel
14
Taxes
13
Gefitinib
13
Cyclophosphamide
13
avelumab
12
atezolizumab
12
durvalumab
11
Albumin-Bound Paclitaxel
11
cemiplimab
9
Radiation
8
Drug Therapy
8
alectinib
7
Injections
7
Etoposide
7
trametinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Non-Small-Cell Lung
×
patritumab deruxtecan
×
Clear all
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled